• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Cepheid, BioGX Partner to Create GeneXpert Monkeypox Test

    Siemens' Varian Gains FDA IDE Nod for FAST-02 Trial

    Acutus Medical Launches AcQCross Line Extension

    Accelmed Partners II, Lauxera Capital Partners Invest in Veranex

    Agnes Lee Named SVP of Investor Relations, Strategic Planning at Inogen
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Theranos Fraud Trial, Part II: The Blame Game Continues

    An Update on Surgical Robotics

    Letting the Light In: How Failure Analysis is the Cornerstone of Success

    Three Talent Strategies to Attract High-Demand Skills

    The Advantages of Bioburden Screening for Sterilization Validation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Cirtec Medical

    Xact Wire EDM Corp.

    JBC Technologies

    Concise Engineering

    BMP Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Investment in Health Startups Drops

    The Power of Leveraging Customer Relationships

    Cost Effective & Efficient Wire EDM Techniques

    How MedTech Professionals Can Help Combat Physician Burnout

    How to Optimize Manufacturing Lines and Choose Which Machines to Buy
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Cirtec Medical

    Xact Wire EDM Corp.

    JBC Technologies

    Concise Engineering

    BMP Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Optimizing Medtech Founder Value

    Would optimizing valuation at seed and A rounds minimize founder dilution for better outcomes?

    Optimizing Medtech Founder Value
    Scott Phillips, CEO, StarFish Medical03.04.20
    Many medical device companies we’ve worked with over the last 20 years have experienced significant outcomes. The founders did well in some cases, and in others, not so well. I wondered whether there was some predictable pattern to the outcomes. Could we act to help founders do better? Would optimizing valuation at seed and A rounds minimize founder dilution for better outcomes? On the surface it seems obvious, but is there data to support my hypothesis?

    Looking at public markets can provide access to data. I found publicly available data on 24 medical device companies that had gone public (assembled by H. Lebret). As part of the listing process they disclosed details of all their prior funding events. Admittedly, there’s a selection bias with choosing startups that chose the public listing route, but the data is consistent and has been well scrutinized. Imperfections in data interpretation are my own (I’m an engineer after all), but I believe the conclusions hold true.

    One story from the data is Cambridge Heart, founded based on research by Dr. Richard Cohen and an early cardiac electrophysiology innovator. MIT had spent a lot of money on securing patents for him and threatened to cut off IP funding unless he commercialized his inventions. He convinced MIT alumnus Jeffrey Arnold to be founding CEO and the company was born. Per publicly available information from the later IPO, Dr. Cohen received 1.25 million founders shares and a smaller number of options. A couple of other co-founders and MIT split another million shares. 

    In the A round of financing, 6.6 million shares were sold at $1 each, giving the company $6.6M to work with. (Interestingly, none of this came from venture capitalists.) When converted to commons they became 3.3 million common shares, so Dr. Cohen’s stake was down to 23 percent. In the B round two years later, another $3.5M was raised in exchange for 1.2M shares, after conversion. Before the company went public, he still owned 14.5 percent of the shares. In all, the company raised only $10.1M. The post IPO value was $167M—a ratio of almost 17x, which certainly helped overcome the equity dilution the founders had to take. Dr. Cohen’s stake was worth $17.7M. Other employees and directors shared $23.1M. It was a very successful outcome for the early visionaries and risk takers.

    Intuitive Surgical, an innovator in robotic endoscopic surgery to allow minimally invasive procedures, is another interesting example. There were four co-founders: Frederic Moll, Robert Younge, John Freund, and the Stanford Research Institute. Similar to the Cambridge Heart case, they later hired another person, Lonnie Smith, as CEO.

    Over three and a half years, the company completed four financing rounds. The first raised $5.4M on a $3.4M valuation—a 62 percent dilution event. They made incredibly efficient use of this capital. A year later they raised $30M at a $44M pre-money valuation for $5 per share. The share price had quintupled in that year. Later that year, they raised $17M at a $119M value for $8 per share. The next round took almost a year to complete and was at the same share price. They raised $41M at a $136M valuation in May 1999. The company did its IPO in June of 2000 at a $301 million post-money valuation. Their timing was miraculous, as the tech crash of 2000 was just around the corner. The founders’ value at exit was $30.4M. It seems the capital efficiency they exhibited with their first round had a dramatic effect in lowering their equity dilution and allowing them to create value.

    The $300M IPO value was a relatively modest 3x more than the $93M raised in those four rounds. Today the company is valued at $70 billion, so it’s gone up over 200x in value from its IPO. Hopefully some of those investors held onto their shares.

    In contrast, consider Inogen, an oxygen concentrator company that went public in 2013. The founders—Alison Bauerlein, Brenton Taylor, and Byron Myers—were students at UC Santa Barbara and won a business plan competition in 2001 for a new type of oxygen concentrator. They diluted 75 percent in their first round to raise $250,000. That’s what happens to students without a track record. From there, they did incredibly well, raising rounds of $5M, $6.6M, and $35.6M at increasing valuations. Then came two down rounds around the time of the 2008 crash. The second was at a lower share price than the original seed round.

    Inogen was lucky to have survived; many companies weren’t so lucky. They brought in a hired gun CEO who received 2.5x as much equity as the founders. Together, they were successful in navigating equity raising and executed a successful IPO. Out of a $418M IPO value, the founders shared $4M. There was an option pool as well, so hopefully they got a piece of that. They built a company with almost 350 employees over 13 years. Today it’s valued at almost $1B.

    The public data set had founder outcomes from $1M to $120M and time to IPO from four to 16 years. I had various hypotheses about what would lead to better founder outcomes. Time would be the entrepreneur’s enemy and longer stories would lead to worse outcomes. Minimizing A-round dilution would drive wealth creation. Large raises and many rounds would work against founder value. I tested the various theories.

    Some broad observations can be made. About half got $20M or more between the founders (Chart 1) and the balance of the companies made far less for their founders. These companies made it to IPO and are often representative of a strong company with a big story. (Second Sight, with a founder exit of $120M, is a special case since Alfred Mann used a lot of his own money from previous successes to build it.)


    Chart 1: Companies and the outcomes the founders achieved.

    Time to exit was weakly correlated with founder outcome. Four of the strongest founder outcomes, (Cambridge Heart, Intuitive Surgical, Hansen Medical, and Biocartis) happened in less than eight years. The average of the rest was over 12 years. Five of the top 10 exits took over ten years. Unfortunately, there’s nothing fast about developing a medical device company to the point where it’s ready for a public listing.

    My best hypothesis was on A-round dilution (Chart 2). I was confident a bunch of early dilution was bad. The data is not so clear. The top three founder exits all had A-round dilutions of 45 percent or lower, but the average of the rest was 59 percent—very close to the average of the rest of the top 10. There was no obvious pattern and correlation is weak; there were a lot of great exits with high early dilution.


    Chart 2: A-round dilution.

    The size of company varied from $30M to $3B and there was no strong correlation. Similarly, the total amount of investment was poorly correlated.

    One value had a strong correlation: exit multiple, or the ratio of IPO value to total investment (Chart 3). It averaged over 16x for the top 10 and was under 4x for the rest. The data isn’t perfect; it doesn’t capture non-share transactions such as founder initial investment. Nonetheless, this correlation is too strong to ignore.


    Chart 3: Ratio of IPO value to total investment.

    I argue exit multiple is the most honest venture efficiency measure. In a simplistic way, it’s the ratio of the clinical value created vs. how expensive it was to get there. This data set seems to say if there’s enough power in the value proposition and market fit, it overcomes issues of dilution, total capital required, time to market, and even early founder dilution. 


    Scott Phillips is CEO of the StarFish group of companies, including StarFish Medical and ViVitro Labs Inc. He holds a degree in engineering physics from the University of British Columbia. Under his leadership, StarFish has grown into a diverse professional organization with clients around the world and a 100 percent focus on medical devices. Scott is a Fellow of The Canadian Academy of Engineering, winner of the EY Entrepreneur Of The Year 2017 Pacific Awards Technology category, 2017 recipient of the VIATEC Technology Champion award, and chairman of the LifeSciences British Columbia board.
    Related Searches
    • heart
    • medical device company
    • cardiac
    • medtech
    Loading, Please Wait..

    Trending
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • FDA OKs J&J Vision's AcuVue Oasys Max 1-Day Contact Lenses
    • How To Overcome The Top 6 Medical Device Manufacturing Challenges
    • Intermountain Healthcare & Siemens Healthineers Open 3 Tellica Outpatient Imaging Centers
    • Labcorp Launches At-Home Collection Device For Diabetes Risk Testing
    Breaking News
    • Cepheid, BioGX Partner to Create GeneXpert Monkeypox Test
    • Siemens' Varian Gains FDA IDE Nod for FAST-02 Trial
    • Acutus Medical Launches AcQCross Line Extension
    • Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
    • Agnes Lee Named SVP of Investor Relations, Strategic Planning at Inogen
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • OEMs Seek Molders Offering Timely Techniques
    • Robotic Surgery: Cutting Through to the Latest
    • Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise
    Shiitake Mushroom Extract Appears Helpful in HPV Infections
    Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
    Coatings World

    Latest Breaking News From Coatings World

    Solvay to Discontinue Use of Fluorosurfactants for Production of Fluoropolymers
    AkzoNobel Names New CEO
    Barentz Showcases Lincoln MFG’s New ISO 9001:2015 Certification
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cepheid, BioGX Partner to Create GeneXpert Monkeypox Test
    Siemens' Varian Gains FDA IDE Nod for FAST-02 Trial
    Acutus Medical Launches AcQCross Line Extension
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
    Pfizer, BioNTech Adapt COVID Vax Against Omicron
    CoreRx Expands Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
    John Frieda Supports the LGBTQIA+ Community
    Athena Club Launches in Canada
    Happi

    Latest Breaking News From Happi

    Fencing Champion Bebe Vio Grandis Named Spokeswoman of L’Oréal Paris
    Past Henkel Exec Christian Chopra Named President of Scotch Porter
    Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
    Ink World

    Latest Breaking News From Ink World

    Barentz Highlights Lincoln MFG’s New ISO 9001:2015 Certification
    Ingevity Appoints Christine Stunyo as Chief Human Resources Officer
    Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Harveer Sahni recognized with Global Achievement Award
    Color-Logic partners with Taktiful 
    ALTANA announces Management Board change
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Andritz Sets Up Wetlace CP Pilot Line in Montbonnot
    Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
    Yanpai Orders Batt Forming Equipment for Needlepunch Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Researchers Discover Novel Patching Material for Bone Defects
    Boston Centerless Opens Second Manufacturing Plant in Indiana
    Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
    LG Display Announces Winners of This Year’s OLEDs GO! Competition
    Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login